Intensity Therapeutics, Inc. Share Price & Technical Analysis
INTS · $4.71 (+1.07%)
Healthcare / Biotechnology
$4.71
+1.07%
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is …
Price chart
Seasonality
May has 1 positive and 2 negative years (last 4 years shown)
-10% return in May, 3% avg return in past 3 year May month.
-67% return in 2026, 24% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -10% | -14% | -21% | -12% | -10% | – | – | – | – | – | – | – | -67% |
| 25 | 15% | 1% | -14% | -71% | -20% | -34% | -12% | 4% | -13% | 184% | -41% | 3% | 3% |
| 24 | -42% | -27% | 40% | -25% | 26% | 0% | 1% | -10% | -12% | -13% | -9% | -42% | -114% |
| 23 | – | – | – | – | – | 0% | 2% | 1% | -32% | -20% | -16% | 248% | 184% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$12.68M
P/E ratio
—
52W high
$43.50
52W low
$4.50
Volume
15,030
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Intensity Therapeutics, Inc. share price today?
- Intensity Therapeutics, Inc. (INTS) last traded around $4.71 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does INTS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for INTS. Download the app for real-time alerts.
- How can I analyze Intensity Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.